研究发现,服用西马格卢提德的2型糖尿病患者患阿尔茨海默氏症的风险降低了70%. Study finds 70% lower Alzheimer's risk for Type 2 diabetes patients on semaglutide.

凯斯西储大学的一项研究表明，在糖尿病药物 Ozempic 和 Wegovy 中发现的索马鲁肽可以降低 2 型糖尿病患者的阿尔茨海默病风险。 A study from Case Western Reserve University indicates that semaglutide, found in diabetes medications Ozempic and Wegovy, may lower Alzheimer's disease risk in Type 2 diabetes patients. 研究人员分析了近100万份健康记录,发现与胰岛素相比风险降低了70%,与其他GLP-1药物相比降低了40%。 Analyzing nearly 1 million health records, researchers found a 70% reduced risk compared to insulin and 40% compared to other GLP-1 drugs. 虽然前景看好,但还需要进一步研究,以证实这些调查结果,并探讨所涉机制。 While promising, further research is needed to confirm these findings and explore the mechanisms involved.